Increasing numbers of pregnant HIV- positive women are receiving combination antiretroviral regimens for preventing mother-to-child virus transmission or for treating the infection itself. Several studies have demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs) induce mitochondrial toxicity by several mechanisms, including depletion of mitochondrial DNA (mtDNA). By the quantification of mtDNA levels, we studied mitochondrial toxicity in HIV-positive women at delivery and the possible correlations with antiretroviral regimens, viroimmunological and metabolic parameters.
Methods
We analysed 68 HIV-positive women enrolled in the Italian Prospective Cohort Study on Efficacy and Toxicity of Antiretroviral in Pregnancy (TARGET Study); all were taking ≥1 NRTI. We quantified mtDNA copies per cell in subcutaneous fat samples collected during delivery. At the 3rd, 6th and 9th month of pregnancy, we collected data concerning CD4+ T-cell count, plasma HIV RNA, total and high-density lipoprotein (HDL) cholesterol, fasting plasma glucose and triglycerides. As a control, we analysed mtDNA levels in abdominal subcutaneous fat samples from 23 HIV-seronegative women at delivery.
Results
mtDNA content was significantly lower in HIV-infected women when compared with HIV-negative controls. mtDNA content varied independently from viroimmunological, lipid and glucose parameters at the different months, with the exceptions of triglycerides at the 9th month and of HDL at the 6th month of pregnancy.
Conclusions
In subcutaneous tissue from women taking NRTI-based antiretroviral regimens, we observed a signifcant decrease of mtDNA content, compared with uninfected women not on antiviral treatment. Moreover, a significant correlation was noted between mtDNA content and HDL cholesterol and triglycerides.
References
1.
European Collaborative Study.Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis2005; 40: 458–465.
2.
NolanD., MallalS.Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther2004; 9: 849–863.
3.
VrouenraetsS.M., TreskesM., RegezR.M.Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment. Antivir Ther2002; 7: 239–244.
4.
FrerichsF.C., DingemansK.P., BrinkmanK.Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med2002; 347: 1895–1896.
ShikumaC.M., HuN., MilneC.Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS2001; 15: 1801–1809.
7.
LewisW., DayB.J., CopelandW.C.Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov2003; 2: 812–822.
8.
LewisW., KohlerJ.J., HosseiniS.H.Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS2006; 20: 675–684.
9.
BrinkmanK., SmeitinkJ.A., RomijnJ.A., ReissP.Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet1999; 354: 1112–1115.
10.
PintiM., SalomoniP., CossarizzaA.Anti-HIV drugs and the mitochondria. Biochim Biophys Acta2006; 1757: 700–707.
11.
CossarizzaA., MoyleG.Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS2004; 18: 137–151.
12.
CossarizzaA., MussiniC., ViganoA.Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: actors or bystanders?Bioessays2001; 23: 1070–1080.
13.
BrinkmanK., ter HofstedeH.J., BurgerD.M., SmeitinkJ.A., KoopmansP.P.Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS1998; 12: 1735–1744.
14.
GerschensonM., BrinkmanK.Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion2004; 4: 763–777.
15.
CherryC.L., GahanM.E., McArthurJ.C.Exposure to dideoxynucleosides is refected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr2002; 30: 271–277.
16.
NolanD., HammondE., MartinA.Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS2003; 17: 1329–1338.
17.
GalluzziL., PintiM., GuaraldiG.Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy. Antivir Ther2005; 10Suppl 2: M91–M99.
18.
MorrisA.A., CarrA.HIV nucleoside analogues: new adverse effects on mitochondria?Lancet1999; 354: 1046–1047.
19.
van der ValkM., CasulaM., WeverlingzG.J.Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther2004; 9: 385–393.
20.
CherryC.L., NolanD., JamesI.R.Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr2006; 42: 435–440.
21.
PaceC.S., MartinA.M., HammondE.L., MamotteC.D., NolanD.A., MallalS.A.Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther2003; 8: 261–263.
22.
ShiramizuB., ShikumaK.M., KamemotoL.Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr2003; 32: 370–374.
23.
TorresS.M., MarchT.H., CarterM.M.In utero exposure of female CD-1 Mice to AZT and/or 3TC: I. Persistence of microscopic lesions in cardiac tissue. Cardiovasc Toxicol2010; 10: 37–50.
LuzzatiR., Del BravoP., Di PerriG., LuzzaniA., ConciaE.Ribofavine and severe lactic acidosis. Lancet1999; 353: 901–902.
26.
SarnerL., FakoyaA.Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect2002; 78: 58–59.
27.
MandelbrotL., KermarrecN., MarcolletA.Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS2003; 17: 272–273.
28.
GerschensonM., KimC., BerzinsB.Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother2009; 63: 1244–1250.
29.
WalkerU.A., BickelM., Lutke VolksbeckS.I.Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr2002; 29: 117–121.
30.
MussiniC., BediniA., BorghiV.CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l. AIDS2005; 19: 287–294.
31.
CossarizzaA., PintiM., MorettiL.Mitochondrial functionality and mitochondrial DNA content in lymphocytes of vertically infected human immunodeficiency virus-positive children with highly active antiretroviral therapy-related lipodystrophy. J Infect Dis2002; 185: 299–305.
32.
CôtéH.C., YipB., AsselinJ.J.Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis2003; 187: 1972–1976.
33.
de MendozaC., de RondeA., SmoldersK.Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses2004; 20: 271–273.
34.
HoyJ.F., GahanM.E., CarrA.Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. J Infect Dis2004; 190: 688–692.
35.
GerschensonM., ShiramizuB., LiButtiD.E., ShikumaC.M.Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther2005; 10Suppl 2: M83–M89.
36.
FloridiaM., GuaraldiG., TamburriniE.Lipodystrophy is an independent predictor of hypertriglyceridemia during pregnancy in HIV-infected women. AIDS2006; 20: 944–947.
37.
FloridiaM., TamburriniE., RavizzaM.Lipid profile during pregnancy in HIV-infected women. HIV Clin Trials2006; 7: 184–193.
38.
SaadiH.F., KurlanderD.J., ErkinsJ.M., HoogwerfB.J.Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil. Endocr Pract1999; 5: 33–36.
39.
EnquobahrieD.A., WilliamsM.A., QiuC., LuthyD.A.Early pregnancy lipid concentrations and the risk of gestational diabetes mellitus. Diabetes Res Clin Pract2005; 70: 134–142.
40.
ClausenT., SlottM., SolvollK.High intake of energy, sucrose, and polyunsaturated fatty acids is associated with increased risk of preeclampsia. Am J Obstet Gynecol2001; 185: 451–458.
